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Abstract 
Background: The objective of this clinical trial (CRS-02) was to assess the efficacy, safety and tolerability of two dosages of the 
herbal medicinal product BNO 1016 (Sinupret extract) in patients with chronic rhinosinusitis (CRS). 
Methodology: 929 patients suffering from CRS were enrolled in this randomised placebo-controlled trial with a treatment period 
of 12 weeks. The primary endpoint was the mean Major Symptom Score (MSS) in week 8 and week 12 compared to placebo. Se-
condary endpoints included further MSS related parameters and responder rates over time. Pharmacoeconomic endpoints were 
also analysed. Finally, safety and tolerability were evaluated.
Results: Sinupret extract was not superior over placebo regarding the primary endpoint. However, the results of the secondary 
endpoints showed a clear trend towards superior efficacy. Therefore, additional post-hoc sensitivity analyses were performed 
in patients with a baseline MSS > 9 and persistence of disease > 1 year diagnosed by specialists in otorhinolaryngology. Those 
patients significantly benefited from Sinupret extract. Therapy was superior for the primary endpoint analysis. Patients were less 
impaired with respect to work and daily activities. A good safety and tolerability of Sinupret extract was assured in all patients. 
Conclusions: Sinupret extract can safely be administered in patients with CRS. Although the primary endpoint of the study was 
not significant, a post-hoc subgroup analysis in patients whose disease was diagnosed by a specialist revealed a pronounced 
treatment effect. Effects in that subgroup were even stronger with longer disease persistence and stronger severity. 
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Introduction
Rhinosinusitis is an inflammation of the nose and the parana-
sal sinuses. Diagnosis is mainly based on signs and symptoms; 
symptoms like nasal blockage or nasal discharge together with 
facial pain, facial pressure, reduction or loss of smell characterize 
the disease. It is considered chronic when symptoms persist for 
more than twelve weeks. It may additionally reveal signs of po-
lyps, mucopurulent discharge, oedema or mucosal obstruction 
when performing a nasal endoscopy. Furthermore, computer to-
mography might show mucosal changes within the ostiomeatal 
complex or the sinuses (1).
Etiology of the disease remains a matter of debate. It is believed 
that chronic rhinosinusitis (CRS) may develop from acute infecti-
ons. The mechanisms and cofounders of transition from acute to 
chronic rhinosinusitis are still under research, but are discussed 
to involve smoking, bacterial or fungal infections, innate and 
adaptive immune dysfunction or allergies (1,2). Recent findings 
also support a relation to patients with severe chronic upper air-
way diseases and suggest neurogenic and systemic pathways (3).
According to EPOS 2012 guideline (European position paper on 
rhinosinusitis and nasal polyps 2012 (4)) and Hastan et al. (5),
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the overall prevalence of CRS may be estimated as around 
11% (range 7-27%) of the general population in Europe and 
considerably impacts physical constitution and quality of life. It 
produces direct costs through consultation visits and antibiotics 
prescriptions as well as indirect costs related to days off work 
and a general loss of productivity (6,7). CRS therefore constitutes a 
major burden for the health care system. Some relief from con-
gestive symptoms can be achieved by application of nasal saline 
spray, nasal lavage with isotonic saline or steam inhalation. 
Besides, pharmacological treatment of CRS includes antibiotics, 
local decongestants, nasal steroids and herbal medicines like 
myrtol or cineol. 
BNO 1016 had been established for use in patients with acute 
rhinosinusitis and is marketed under the brand name ‘Sinupret 
extract CT’. It contains the dry extract of five herbal drugs, name-
ly gentian root, primula flower, sorrel herb, elder flower, verbena 
herb, in a ratio of 1:3:3:3:3. The efficacy in acute rhinosinusitis 
has been demonstrated in a randomised, placebo-controlled 
trial (8). In this clinical trial Sinupret extract was applied three 
times daily at a dose of 160 mg each. In this study (ARhiSi-2), 
Sinupret extract demonstrated to be clinically and significantly 
superior versus placebo in terms of reduction of symptoms as 
measured by the reduction in the Major Symptom Score (MSS; 
p=0.008). Furthermore, the proportion of patients having been 
cured (MSS ≤ 1) was significantly higher in the active treatment 
group than in the placebo group (48.4% vs. 35.8%; p=0.0063). 
Additionally, more patients were free of signs of rhinosinusal 
inflammation in the ultrasound investigation (73.2% vs. 61.6%; 
p=0.0131) (8).
The tolerability of Sinupret extract was comparable to that of 
placebo. About 95% of the patients rated tolerability to be ‘very 
good’ or ‘good’ (8). 
The present study CRS-02 extended the efficacy evaluation to 
the indication of chronic rhinosinusitis.  
Materials and methods
Study design
The CRS-02 study was designed as a multicentre, randomised, 
double-blind, placebo-controlled, parallel group trial to assess 
efficacy as well as safety and tolerability of two dosages of Si-
nupret extract in patients with CRS. It was conducted from Sep-
tember 2012 to April 2014 in 67 trial centres in Belgium, Czech 
Republic, Germany and Poland. The investigations were led by 
specialists in otorhinolaryngology as well as internal medicine 
and general practitioners. Trial participants passed through the 
study with ambulatory treatments. A hospitalisation did not take 
place. The study included a screening period of up to 2 weeks 
(visit 1), a 12-week treatment period (visit 2 to 6) and an 8-week 
follow-up period (visit 7). Patients were randomised at day 1 
(visit 2) and control visits were scheduled after 1 week (visit 3), 4 
weeks (visit 4), 8 weeks (visit 5), and 12 weeks (visit 6). Follow-up 
examination was scheduled 8 weeks after visit 6, adding up to a 
total trial duration of 20 weeks.
The study was conducted in accordance with the Declaration of 
Helsinki (9) and the ICH Guideline for Good Clinical Practice (11). It 
was also approved by the relevant competent authorities of the 
participating countries and received a favorable opinion by the 
competent ethics committees. Written informed consent was 
obtained from all patients prior to inclusion.
Patients
In the CRS-02 study, adult male and female outpatients with 
the following criteria were eligible: 18 to 75 years of age with 
bilateral CRS without nasal polyps confirmed by endoscopy (op-
tional computer tomography not older than 2 years). Symptoms 
had to be present for at least 12 weeks prior to enrolment wit-
hout complete resolution. Total MSS score (8,10) had to be 6 to 12 
points and rhinorrhea and pain (facial pain or headache) had to 
be of at least moderate intensity (MSS score at least 2).
Exclusion criteria were: sinus surgery during the past 2 years, 
CRS due to allergic origin, treatment with systemic or nasal 
antibiotics or corticosteroids within the last 4 weeks prior to 
inclusion and patients treated with decongestant preparations, 
analgesics, mucolytics/secretolytics, antihistamines, or alterna-
tive medicine preparations for treatment of common cold like 
symptoms or with immunomodulating drugs within the last 7 
days prior to inclusion. 
Treatments
At baseline (visit 2), patients were randomised in a 1:1:1 ratio 
to receive either Sinupret extract 240 mg per day, 480 mg per 
day or placebo in a double-blind mode. Sinupret extract was 
provided as coated tablets containing 80 mg of the dry extract 
of the five herbal drugs. Study medication was administered 
orally. Each patient received two tablets three times daily, either 
Sinupret extract 80 mg, matching placebo or a combination of 
both.
Assessments
At each visit, patients were evaluated by the investigator for 
the five symptoms of the Major Symptom Score (MSSINV). These 
are rhinorrhea/anterior discharge, postnasal drip, nasal con-
gestion, headache, and facial pain or pressure. Patients recorded 
symptoms in a diary (MSSPAT) at five days during the screening 
period, while days could be chosen in an arbitrary way. More-
over, they recorded symptoms on a daily basis between visit 
5 (week 8) and 6 (week 12). The severity of each of the five 
symptoms was indicated on a 4-point rating scale of increasing 
severity (0 = none; 1 = mild; 2 = moderate; 3 = severe). The MSS 
was calculated as the sum of the five individual symptom scores.
Patients and investigators assessed the response to treatment 
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assessed by the investigator and the patient, the mean severity 
of single symptoms and responders rates over time.
Pharmacoeconomic endpoints were defined as the number of 
days off work or missed daily activities, the percentage of work 
time missed, the percentage of impairment while working due 
to health, the percentage of overall work impairment and the 
percentage of activity impairment due to health (all taken from 
the WPAI:GH-questionnaire. Finally, safety was analysed as the 
number of patients with adverse events, the number of patients 
by tolerability score and regarding changes in vital signs and 
laboratory parameters.
Statistical methods
A pre-planned interim analysis was performed in March 2013 to 
re-estimate sample size. The interim analysis used the efficacy 
data of 375 patients without unblinding treatment assignment. 
Based on the updated variance data for the primary endpoint, 
the sample size had been increased from 771 to 900 patients. 
The analyses of the primary and secondary endpoints were 
using the full analysis set (FAS) which included all randomised 
patients with at least one administration of study drug and 
available post-baseline efficacy data. The safety population des-
cribed by the safety evaluable set (SES) included all randomised 
patients with at least one documented administration of trial 
medication and any post-baseline safety data. The per protocol 
set (PPS) was additionally evaluated as sensitivity analysis. 
Moreover, post-hoc sensitivity analyses considered patients with 
a baseline MSS > 9, patients recruited by otorhinolaryngologists 
and patients with a persistence of CRS > 1 year.
The primary efficacy endpoint was tested using a superiority hy-
pothesis versus placebo employing ANCOVA with ‘MSS at Base-
line’ as a fixed effect covariate and ‘Treatment’ as a fixed effect. 
The centre effect described by the variable ‘Medical Specialist” 
was included in the model as fixed effect. The Null hypotheses 
were tested with a one-sided type-I error rate of 2.5% (adjusted 
for two confirmatory tests according to Benjamini-Hochberg) (12). 
Secondary endpoints were analysed in an explorative manner. 
Standard descriptive statistics were used for the analysis of se-
condary efficacy endpoints, pharmacoeconomic endpoints and 
safety data. Continuous variables were described by median and 
mean values. Standard deviation, quartiles, minimum and maxi-
mum were used as indices of variability. Categorical variables 
were described as absolute numbers and percentages. All data 
were analysed using the software package SAS release 9.2 (SAS 
Institute Inc., Cary, NC, USA) (13). Missing efficacy values except 
for the SNOT-20 GAV analysis were handled by a mixed model 
for repeated measures that assumes that missing values are ‘mis-
sing at random’ (MAR) (primary estimate). A sensitivity analysis 
was included, to assess the robustness of the primary estimate 
with regard to missing data. MAR assumptions were replaced 
by assumptions that were likely to be relatively less favorable 
at visit 3 (week 1) to 6 (week 12) based on a 4-point rating scale 
(0 = symptom healed; 1 = symptom improved; 2 = symptom 
unchanged; 3 = symptom deteriorated). Patients with healed or 
improved symptoms were classified as responders.
The participants assessed the total symptom severity on a 
visual analogue scale at visit 2 (day 1) to visit 7 (week 20) with 
0 mm meaning ‘not troublesome' and 100 mm meaning ‘worst 
thinkable troublesome’. The Sino-Nasal Outcome Test-20 (SNOT-
20) in the German adapted version (SNOT-20 GAV) was used 
to evaluate the impact of rhinosinusitis symptoms on health-
related quality of life (HRQoL). Patients rated the severity of the 
20 questionnaire items retrospectively for the last 24 hours at 
baseline and at each post-baseline visit using a 0-5 point Likert 
scale (0 = not present / no problem; 1 = very mild problem; 2 
= mild or slight problem; 3 = moderate problem; 4 = severe 
problem; 5 = problem as bad as it can be). The SNOT-20 GAV was 
used only in German centres. 
At each visit starting from day 1, patients were asked to report 
any unscheduled physician consultation for CRS-related 
symptoms, CRS-related days off work or missed daily activities 
since the last visit. Participants answered the Work Productivity 
and Activity Impairment: General Health (WPAI:GH) question-
naire to measure impairments in work and activities during the 
previous week. 
Safety and tolerability were evaluated based on the frequency 
and severity of adverse events, measurement of vital signs and 
analysis of laboratory parameters and physical examinations. 
Patients and investigators were asked to judge the tolerability 
at the end of the treatment period using a 5-point rating scale 
ranging from 0 (‘very good’) to 4 (‘very poor’).
Endpoints
The primary endpoint was the mean MSS assessed by the in-
vestigator (MSSINV) at visit 5 (week 8) and visit 6 (week 12). A dif-
ference of D 0.80 score points in the primary endpoint between 
the active treatment (high and low dose) and placebo was 
considered to be clinically relevant. In the preceding clinical trial 
in acute rhinosinusitis (8) a minimal clinical important difference 
of D 1.0 score points was chosen and confirmed by otorhinologi-
cal experts. However, in contrast to an acute state of the disease, 
improvements in the chronic state are generally slower and not 
as conspicuous for the patient and the investigator. Therefore, D 
was reduced to 0.8 which was again confirmed by the experts. 
The investigator based score was chosen following a former 
decision of the competent German authority on the correspon-
ding clinical trial in acute rhinosinusitis. Patient based evalua-
tions were included as secondary efficacy endpoints (8) . Major 
secondary efficacy endpoints included the mean MSSPAT at visit 
5 (week 8) and visit 6 (week 12), change of mean MSSINV over 
time on each visit starting from visit 3 (week 1) until visit 7 (week 
20), discrete and mean symptom scores for single MSS items 
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to the treatment or in case of SNOT-20 GAV by worst category 
as long as only one item per subscore was missing. All reported 
probability (p) values in this publication are two-sided p-values 
unless otherwise specified.
Results
Patient disposition
The disposition of patients is displayed in Figure 1. In total, 929 
patients were randomised and received investigational treat-
ment (240 mg N=318; 480 mg N=305; placebo N=306). These 
patients constituted the SES. Fourteen patients were excluded 
from the efficacy analysis for major protocol violations (no 
post-baseline efficacy data available for 11 patients; emergency 
envelopes opened for 3 patients). The PPS consisted of 603 
patients, i.e. 326 patients were excluded for 482 major protocol 
deviations.
The most common (>5% of all protocol violations) were:
• Unpermitted administration of paracetamol one day before 
visits 2, 5 or 6, i.e. before baseline, week 8 or week 12 
(17.9%)
• Failure to meet the inclusion criteria with respect to the 
intensity of rhinorrhoea and pain (11.7%) or MSS severity 
(7.3%)
• Antibiotic use during the 4 weeks prior to inclusion (7.9%)
• Use of prohibited medication before or during the study 
(6.0%)
• Analgesic use within three days prior to visits 2, 5 or 6, i.e. 
before baseline, week 8 or week 12 (5.6%) 
• Missing primary endpoint data at visit 5 (week 8) (5.4%).
Overall, 81 patients discontinued the study prematurely, 66 
during the treatment period and 15 afterwards. The main rea-
sons were non-tolerable adverse events (N=20), withdrawal of 
consent (N=23) and application of non-permitted concomitant 
medication (N=16).
Assessment of the patients’ demographic and baseline characte-
ristics indicated that all groups were adequately balanced. Mean 
age was 44.3 ± 14.8 years and 61.4% of all patients were women. 
The median treatment duration was 85 days (≈12 weeks).
Efficacy results
Baseline MSSINV scores on visit 2 (day 1) of the trial were 10.7 (240 
mg), 10.7 (480 mg) and 10.8 (placebo) score points (p>0.05, FAS). 
Treatment with Sinupret extract was not superior over placebo 
at the primary endpoint analysis with mean MSSINV (averaged for 
visit 5 and 6, i.e. week 8 and week 12) of 5.1 (240 mg), 5.1 (480 
mg) and 5.3 (placebo) score points (p>0.05, FAS). However, the 
results of the secondary efficacy endpoints indicated that daily 
treatment with Sinupret extract for 12 weeks was effective in im-
proving symptoms and health related quality of life in patients 
with CRS. In general, all patient assessments were similar and re-
flected the results of the assessments done by the investigators.
Discontinued Discontinued Discontinued
in treatment period N=23 in treatment period N=24 in treatment period N=19
after treatment period N=4 after treatment period N=5 after treatment period N=6
Reason for discontinuation Reason for discontinuation Reason for discontinuation
Adverse Event N=5 Adverse Event N=9 Adverse Event N=6
Withdrawal of consent N=9 Withdrawal of consent N=8 Withdrawal of consent N=6
Not permitted concomitant medication N=4 Not permitted concomitant medication N=7 Not permitted concomitant medication N=5
Lost to follow-up N=4 Lost to follow-up N=1 Lost to follow-up N=1
Disease progression / Lack of efficacy N=1 Disease progression / Lack of efficacy N=1 Disease progression / Lack of efficacy N=0
Poor compliance N=0 Poor compliance N=1 Poor compliance N=2
Pregnancy N=0 Pregnancy N=0 Pregnancy N=1
Harmful situation for the patient N=1 Harmful situation for the patient N=0 Harmful situation for the patient N=0
Exclusioin criteria N=0 Exclusioin criteria N=1 Exclusioin criteria N=2
Other reasons N=3 Other reasons N=1 Other reasons N=2
SES N=318 SES N=305 SES N=306
FAS N=309 FAS N=303 FAS N=303
PPS N=205 PPS N=208 PPS N=190
Analysed Analysed Analysed
Screened 
N=1190
Screening failures 
N=263
Randomised and treated 
N=929
Sinupret extract 240mg 
N=318
Sinupret extract 480mg 
N=305
Placebo 
N=306
Figure 1. Patient disposition.
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Significant differences in favor of Sinupret extract were demon-
strated for the investigator assessments from visit 3 (week 1) to 
visit 7 (week 20) for rhinorrhea, headache and facial pain/pressu-
re. Patients assessed facial pain/pressure and the total symptom 
severity as significantly improved compared to placebo.
As assessed by the WPAI:GH, patients treated with Sinupret 
extract had a significantly greater improvement compared 
to placebo-treated patients regarding the outcome ‘percent 
impairment while working due to health’ at visit 7 (week 20), and 
regarding the outcome ’percent overall work impairment due to 
health’ at visit 5 (week 8) and visit 7 (week 20). Finally, no treat-
ment effect was seen regarding the other outcomes generated 
from the WPAI:GH (‘percent work time missed due to health’ and 
‘percent activity impairment due to health’). 
Post-hoc sensitivity analysis
Subgroup analyses on the clinical data obtained were first per-
formed considering usual factors like demographics or possible 
country and site effects. Analyses did not reveal definite hints 
on possible treatment relations.  Subgroup analyses on more 
disease related confounders were performed as well. As a strong 
placebo effect could be observed, initial baseline symptoms 
might not have been severe enough to demonstrate a clear 
differentiation between treatments at the end of the trial. It was 
expected, that among all investigators, the specialists in otor-
hinolaryngology are most competent in making CRS diagnose. 
Therefore, the subgroup was restricted to patients who were 
diagnosed and treated by specialists in otorhinolaryngology. 
Resulting factors for predicting a treatment differentiation 
were chosen as 1) specialist in otorhinolaryngology, 2) severe 
Sinupret extract
240 mg
Sinupret extract
480 mg
Placebo p-value vs. Placebo
240 mg / 480 mga
Averaged MSSINV visit 2 (day 1) (baseline); Mean (SD)
N=86 N=93 N=75
10.7 (0.8) 10.7 (0.8) 10.8 (0.8)
Averaged MSSINV visit 5 (week 8) and visit 6 (week 12); Mean (SD)
N=86 N=93 N=75
6.3 (2.7) 5.3 (2.8) 6.8 (3.4) 0.3224 / 0.0015
Averaged single MSSINV items visit 5 (week 8) and visit 6 (week 12); Mean (SD)
N=86 N=93 N=75
Rhinorrhea anterior 1.3 (0.6) 1.0 (0.7) 1.5 (0.8) 0.1080 / <0.001
Rhinorrhea posterior 1.6 (0.6) 1.3 (0.7) 1.5 (0.8) 0.6691 / 0.1392
Nasal congestion 1.4 (0.7) 1.2 (0.8) 1.4 (0.8) 0.9566 / 0.1827
Headache 1.0 (0.7) 0.8 (0.7) 1.2 (0.9) 0.2070 / 0.0101
Facial pain 1.1 (0.7) 0.9 (0.7) 1.2 (0.8) 0.1781 / 0.0009
Table 1. Results of single items of the MSSINV in subgroup of patients who had a baseline MSS > 9, had CRS persistence > 1 year and were treated by a 
specialist in otorhinolaryngology (FAS).
Figure 2. Mean MSSINV (± SEM) in subgroup of patients who had a 
baseline MSS >9, had CRS persistence >1 year and were treated 
by a specialist in otorhinolaryngology (FAS).
a ANCOVA with ‘MSS at Baseline (visit 2, day 1)’ as a fixed effect covariate and ‘Treatment’ as a fixed effect. The centre effect described 
by the variable ‘Medical Specialist’ was included in the model as fixed effect.
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symptoms at baseline, i.e. MSS > 9, and 3) a long persistence of 
the chronic disease, i.e. > 1 year. Implementing these specifica-
tions, treatment effects with respect to the primary endpoint, 
i.e. average MSSINV at visit 5 (week 8) and visit 6 (week 12) was 
statistically significant in favor of Sinupret extract 480 mg (Table 
1) and showed a clinically relevant difference.
In detail, the between group difference (LSMEAN) was statisti-
cally significant for the high dose group compared to placebo 
after 12 weeks (D 1.90 score points, p=0.003) and 20 weeks (D 
2.01 score points, p=0.005, Figure 2).
Moreover, analysis of the single items of the MSSINV over visit 
5 (week 8) and visit 6 (week 12) revealed significantly superior 
treatment effects for the higher dose with respect to rhinor-
rhea anterior, headache and facial pain/pressure compared to 
placebo (Table 1). The significant effect persisted until visit 7 
(week 20) for rhinorrhea anterior and facial pain/pressure (data 
not shown). Additionally, treatment effect of the 480 mg was 
significantly different from placebo with respect to rhinorrhea 
posterior at visit 7 (week 20) (data not shown).
The patient assessment of the total symptom severity was 
significantly less at week 12 (p=0.0012) and week 20 (p=0.0046) 
when they received Sinupret extract 480 mg compared to 
placebo.
Patients treated with the higher dose were significantly less 
Table 2. Results of the WPAI:GHPAT in subgroup of patients who had a baseline MSS > 9, had CRS persistence > 1 year and were treated 
by a specialist in otorhinolaryngology (FAS).
Sinupret extract
240 mg
Sinupret extract
480 mg
Placebo p-value vs. Placebo
240 mg / 480 mga
Percent overall work impairment due to health; Mean (SD)
N=53 N=52 N=54
Baseline (day 1) 52.3 (22.5) 51.3 (20.3) 52.0 (22.4)
Visit 5 (week 8) 40.0 (19.4) 29.5 (15.4) 40.0 (25.7) 0.6697 / 0.0036
Visit 6 (week 12) 34.8 (19.1) 21.9 (18.2) 41.9 (28.2) 0.0622 / <0.001
Visit 7 (week 20) 31.7 (21.8) 17.6 (17.0) 39.7 (29.2) 0.0282 / <0.001
Percent work time missed due to health; Mean (SD)
N=54 N=52 N=54
Baseline (day 1) 5.4 (17.4) 2.0 (5.7) 5.6 (16.7)
Visit 5 (week 8) 4.6 (16.6) 3.2 (15.4) 4.0 (19.0) 0.6315 / 0.2938
Visit 6 (week 12) 3.1 (15.3) 8.0 (24.4) 5.7 (19.9) 0.2755 / 0.8777
Visit 7 (week 20) 3.7 (17.4) 3.5 (15.7) 0.5 (2.4) 0.2070 / 0.4676
Percent impairment while working due to health; Mean (SD)
N=55 N=55 N=58
Baseline (day 1) 54.5 (22.8) 53.3 (20.5) 54.8 (22.5)
Visit 5 (week 8) 41.1 (19.8) 31.4 (16.0) 40.7 (25.6) 0.9580/ 0.0182
Visit 6 (week 12) 35.0 (19.2) 23.5 (20.9) 43.2 (28.8) 0.803 / 0.0003
Visit 7 (week 20) 31.1 (21.0) 17.8 (18.7) 38.9 (29.4) 0.0572 / <0.001
Percent activity impairment due to health; Mean (SD)
N=86 N=93 N=74
Baseline (day 1) 56.0 (20.6) 54.8 (20.8) 60.8 (20.1)
Visit 5 (week 8) 41.1 (21.5) 36.4 (21.2) 44.5 (24.9) 0.7325 / 0.1328
Visit 6 (week 12) 32.9 (21.0) 28.5 (22.5) 44.5 (28.5) 0.0192 / 0.0019
Visit 7 (week 20) 32.5 (23.2) 25.4 (24.4) 38.1 (26.8) 0.4086 / 0.0135
a ANCOVA with ‘MSS at Baseline (visit 2, day 1)’ as a fixed effect covariate and ‘Treatment’ as a fixed effect. The centre effect described by the variable ‘Medical Specialist’ was 
included in the model as fixed effect.
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impaired compared to placebo-treated patients as could be 
taken from the WPAI:GH-items ‘impairment while working due 
to health’ at visits 5, 6 and 7 (i.e. weeks 8, 12 and 20), as well as 
from the items ‘overall work impairment due to health’ and ‘acti-
vity impairment due to health’ at visit 6 and visit 7 (i.e. weeks 12 
and 20). No significance was seen regarding ‘percent work time 
missed due to health’ (Table 2).
Safety and tolerability
In total, 1,215 adverse events were reported by 528 (57.0%) 
patients during the treatment period and 150 adverse events 
by 109 (11.7%) during the follow-up. Most of the events were of 
mild to moderate intensity. A relationship with the study drug 
was suspected in 14 patients (4.4%) treated with Sinupret ex-
tract 240 mg; in 18 patients (5.9%) treated with the 480 mg and 
in 12 patients (3.9%) who received placebo (Table 3). 
The most common drug-related adverse events reported for the 
240 mg, the 480 mg and placebo were upper abdominal pain 
(1.3%, 1.3%, 0.7%), diarrhoea (0.6%, 0.3%, 1.3%) and headache 
(0.3%, 1.3%, 0.7%). 
Serious adverse events were noted in 11 patients (1.2%) during 
the treatment period and in 5 (0.5%) patients during the follow-
Table 3. Number of patients with adverse events (SES).
Sinupret extract
240 mg
Sinupret extract
480 mg
Placebo Total
Patients with at least one adverse events during the treatment period (baseline to week 12)
N=318 N=305 N=306 N=929
Adverse Event 172 (54.1%) 172 (56.4%) 184 (60.1%) 528 (56.8%)
Serious Adverse Event 6 (1.9%) 3 (1.0%) 2 (0.7%) 11 (1.2%)
Drug-related Adverse 
Event
14 (4.4%) 18 (5.9%) 12 (3.9%) 44 (4.7%)
Discontinuation due to 
Adverse Event
5 (1.6%) 9 (3.0%) 6 (2.0%) 20 (2.2%)
Patients with at least one adverse events during the follow-up (week 12 to 20)
N=318 N=305 N=306 N=929
Adverse Event 35 (11.0%) 25 (8.2%) 49 (16.0%) 109 (11.7%)
SAE 2 (0.6%) 1 (0.3%) 2 (0.7%) 5 (0.5%)
Patients with most frequent drug-related adverse events during the treatment period (baseline to week 12)
N=318 N=305 N=306 N=929
Upper abdominal pain 4 (1.3%) 4 (1.3%) 2 (0.7%) 10 (1.1%)
Diarrhoea 2 (0.6%) 1 (0.3%) 4 (1.3%) 7 (0.8%)
Headache 1 (0.3%) 4 (1.3%) 2 (0.7%) 7 (0.8%)
Nausea 3 (0.9%) 2 (0.7%) 1 (0.3%) 6 (0.6%)
Rash 1 (0.3%) 2 (0.7%) 2 (0.7%) 5 (0.5%)
Abdominal pain 1 (0.3%) 2 (0.7%) 0 (0%) 3 (0.3%)
Nasopharyngitis 1 (0.3%) 2 (0.7%) 0 (0%) 3 (0.3%)
Pruritus 1 (0.3%) 1 (0.3%) 1 (0.3%) 3 (0.3%)
Number of adverse events during the treatment period by intensity (baseline to week 12)
384 (100%) 376 (100%) 455 (100%) 1215 (100%)
Unknown 2 (0.5%) 4 (1.1%) 0 (0%) 6 (0.5%)
Mild 264 (68.8%) 267 (71.0%) 312 (68.6%) 843 (69.4%)
Moderate 102 (26.6%) 97 (25.8%) 125 (27.5%) 324 (26.7%)
Severe 16 (4.2%) 8 (2.1%) 18 (4.0%) 42 (3.5%)
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up period. No causal relationship with the study medication was 
seen for all of these. One patient with 2 serious adverse events 
(liver and pancreatic disorder) reported during the follow-up 
period and a medical history of pancreatopathy since 2012 died 
during the post-treatment period (240 mg group). The investi-
gator considered all adverse events of this patient not related to 
the investigational drug. 
Adverse events led to discontinuation in 20 patients (2.2%). The 
incidence of adverse events leading to premature discontinua-
tion was highest in the 480 mg group (3.0%) compared to the 
240 mg group and placebo (1.6% and 2.0%, respectively). No 
medically relevant differences in laboratory parameters or vital 
signs were observed for patients treated with Sinupret extract 
compared to placebo. 
Tolerability was assessed as ‘very good’ or ‘good’ by 89.6%, 88.5% 
and 91.2% of the investigators and by 86.8%, 86.2% and 82.9% 
of the patients (240 mg, 480 mg and placebo, respectively).
 
Discussion
Chronic rhinosinusitis is a disabling disease, for which single 
medications are so far not registered; therefore, surgery is con-
sidered frequently. The current clinical trial failed to show superi-
ority over placebo with respect to the primary endpoint in the 
overall patient population. However, results of the secondary 
endpoints indicated that Sinupret extract improves symptoms 
in CRS patients, primarily facial pain or pressure, headache, and 
rhinorrhoea. Furthermore, daily treatment with Sinupret extract 
for about 12 weeks demonstrated a safety profile comparable to 
placebo. 
The outcome of the primary endpoint was assumed to be a 
result of a strong placebo effect. This could be based on patients 
not really suffering from chronic rhinosinusitis (as patients 
were partially diagnosed by non-specialists), or suffering from 
symptoms not severe enough to demonstrate a clear difference 
between treatments. Moreover, a selection bias in cases of those 
individuals included in this study by non-otorhinologists could 
not be ruled out. Additional post-hoc sensitivity analyses identi-
fied possible modifiers of treatment success. Within a population 
with more severe and more persistent chronic disease, positive 
findings on the efficacy of Sinupret extract were substantia-
ted. Patients with a baseline MSS above 9, a persistence of the 
disease of more than 1 year, and those who were diagnosed and 
treated by a specialist in otorhinolaryngology, had a significant 
benefit from the treatment. The 480 mg dose was considerably 
effective in most outcome measures. The averaged MSSINV was 
significantly reduced at visit 5 (week 8) and 6 (week 12) com-
pared to placebo. At visit 6 (week 12) and visit 7 (week 20) the 
difference was clinically relevant and statistically significant. 
Superior treatment effects were observed for rhinorrhoea 
anterior, headache and facial pain/pressure for the 480 mg dose. 
Symptoms were less severe at visit 6 (week 12) and visit 7 (week 
20) and the patients were less impaired with respect to work 
and daily activities. Consequently, the results of these subgroup 
analyses reveal that diagnosis by a specialist in otorhinolaryngo-
logy remarkably impacts the treatment effect. The latter result is 
also in line with an observational study on 91 patients with CRS 
who underwent consultation by a specialist in otorhinolaryn-
gology (14). The authors hypothesized that proper treatment by 
a specialist in otorhinolaryngology is a major factor for a good 
improvement of the disease in CRS patients. Therefore, specialist 
consultation possibly facilitates proper diagnosis and treatment 
initiation.
Persistence and severity of the disease also influenced the ef-
ficacy outcomes in the present study. The severity of the disease 
is already reflected in the EPOS 2012 guideline (1). It differentiates 
between mild and moderate/severe disease in adults with CRS 
and its respective management scheme. Generally, treatment 
options recommended in the guideline focus on nasal saline 
irrigation and topical corticosteroids. Additionally, long-term an-
tibiotics should be considered in more severe forms of a CRS (1).
Nasal saline irrigation is intended to transport mucus and to 
soothe mucous membrane irritation, topical corticosteroids 
work against inflammation and subsequent swelling, and finally 
antibiotics target microbial biofilms in the sinuses. However, it is 
obvious that in particular the latter treatments often exhibit re-
markable side effects. These may not be neglected even if their 
severity might only be less pronounced, as in the chronic state 
of the disease medication generally has to be administered for a 
longer time period or even as a long-term treatment.
As the herbal medicinal product Sinupret extract holds mucoly-
tic/mucokinetic, anti-inflammatory, as well as anti-viral and anti-
bacterial properties in ex vivo studies (15), it ideally fits treatment 
recommendations for moderate/severe CRS. Major symptoms of 
CRS are identical with those recognised in the acute state of the 
disease. From an etiological point of view CRS is believed to de-
velop from the acute state, and for this reason, similar symptoms 
like inflammation, oedema and breathing difficulties are present 
in both diseases. Therefore, one can suggest that a beneficial 
treatment for the acute state might be a good treatment option 
for the chronic state as well. Sinupret extract is supposed to be 
such a suitable herbal alternative for the treatment of acute and 
of chronic symptoms.
Efficacy and safety of Sinupret extract (480 mg/day) for the tre-
atment of acute rhinosinusitis could already be demonstrated in 
the randomized, controlled, double blind, multicenter ARhiSi-2 
trial in 386 patients suffering from symptoms characterised by 
an acute onset (8). Patients with symptom duration of ≤3 days, 
mild to moderate facial pain and an MSS of ≥ 8 and ≤ 12 were 
treated for 15 days. Primary and secondary endpoints in the 
study were comparable to the current trial. The MSS improved 
progressively over the course of the 15-day-treatment in the 
active treatment and placebo by a mean of 7.4 to 2.4 with Sinu-
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